ArticleBMC cancer2024

Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2-positive early breast cancer: real-world data from NeoPowER study.

Fabio Canino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.